NGS-Based ctDNA Profiling After the Resistance of Second-Line Osimertinib for Patient with EGFR-Mutated Pulmonary Adenocarcinoma

Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is effective in T790M positive non-small-cell lung cancer (NSCLC). Despite the efficacy of osimertinib, patients inevitably develop resistance and the mechanisms of osimertinib resistance are het...

Full description

Saved in:
Bibliographic Details
Published in:OncoTargets and therapy 2021-01, Vol.14, p.4261-4265
Main Authors: Li, Dan, Yang, DaFu, Cui, SaiQiong, Pan, Evenki, Yang, Peng, Dai, ZhaoXia
Format: Article
Language:English
Subjects:
Adenocarcinoma
Antigens
Binding sites
Biopsy
Cancer therapies
Care and treatment
Case Report
Consent
Development and progression
Epidermal growth factor
Epidermal growth factor receptors
Evolution & development
FDA approval
Gene amplification
Genotyping
Kinases
Lung cancer
Lung cancer, Non-small cell
Mutation
Non-small cell lung carcinoma
Patients
Plasma
Protein-tyrosine kinase
Racial profiling
Small cell lung carcinoma
Tyrosine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), is effective in T790M positive non-small-cell lung cancer (NSCLC). Despite the efficacy of osimertinib, patients inevitably develop resistance and the mechanisms of osimertinib resistance are heterogeneous. Here, we report that a lung adenocarcinoma patient with L858R mutation who was treated with second-line osimertinib therapy acquired multiple resistance to osimertinib by the non-invasive circulating tumor DNA (ctDNA) genotyping. This case provides the possible mechanisms of osimertinib resistance that occur during the disease progression and supports the longitudinal monitoring of ctDNA for the detection of novel acquired resistance and tumor heterogeneity.
ISSN:1178-6930
1178-6930
DOI:10.2147/OTT.S318250